3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
8
Neoplasm Metastasis
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Endometrial Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Interventions
pembrolizumab
7
Nivolumab
6
enfortumab vedotin
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
4
sacituzumab govitecan
3
Docetaxel
3
CTLA-4 Antigen
3
cabozantinib
2
Taxes
2
Paclitaxel
2
Gemcitabine
2
temsirolimus
1
relatlimab
1
lenvatinib
1
eribulin
1
avelumab
1
atezolizumab
1
Valproic Acid
1
Sirolimus
1
Single Person
1
Radiosurgery
1
Platinum
1
Immunoglobulin G
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
trastuzumab deruxtecan
×
30 days
×
Clear all
No trials found.